AB-1002 is an investigational one-time gene therapy that promotes increased production of protein inhibitor 1.
The phase 3 SELECT-GCA study evaluated the efficacy and safety of upadacitinib in patients 50 years of age and older with GCA.
Tavapadon is an oral, once-daily, selective dopamine D1/D5 receptor partial agonist designed to improve motor control while avoiding D2/D3 overstimulation.
Selarsdi is supplied as 45mg/0.5mL and 90mg/mL single-dose prefilled syringes.
LX2006 (AAVrh.10hFXN) is an adeno-associated virus gene therapy candidate designed to deliver a functional frataxin gene to cardiac cells to improve mitochondrial function.
The phase 3 study evaluated the efficacy and safety of lumateperone as an adjunctive treatment to antidepressants in 485 patients with MDD.
DefenCath is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anticoagulant
Tyenne is now available as a 20mg/mL single-dose vial (80mg/4mL, 200mg/10mL, or 400mg/20mL) for further dilution prior to IV infusion.
The Repatha Pushtronix System will be discontinued as of June 30, 2024.
NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway.
